EU completes Meridia review
Executive Summary
EU Committee for Proprietary Medicinal Products "issued a positive opinion reaffirming the favorable risk/benefit profile of sibutramine," Abbott announces June 27. The committee reviewed the obesity drug (Meridia in the U.S.) at the request of Italian Health Ministry after the agency suspended approval of sibutramine. Abbott expects FDA to respond by the fall to a petition from Public Citizen's Health Research Group asking that Meridia be withdrawn (1"The Pink Sheet" June 17, p. 16)...
You may also be interested in...
Meridia Growth Forecast Is 50% In 2002, Despite Italian Withdrawal – Abbott
Abbott's revised forecast for the anti-obesity agent Meridia (sibutramine) still assumes a 50% increase in worldwide sales for 2002
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.